Svar Life Science

March 3, 2021

NEW PAPER: Complement components as prognostic markers of the outcome of critically ill COVID-19 patients

In some patients, COVID-19 can cause acute respiratory distress syndrome (ARDS). This is a very serious condition that causes alveolar damage to the lungs, can cause pulmonary thrombosis and often requires ventilator support. A majority of patients undergoing treatment for COVID-19 in intensive care units have developed ARDS.

In a recent paper, Miklós Lipcsey and colleagues have studied components of the intravascular innate immune system (IIIS) in relation to COVID-19 ARDS.

March 3, 2021

NEW PAPER: Complement components as prognostic markers of the outcome of critically ill COVID-19 patients

In some patients, COVID-19 can cause acute respiratory distress syndrome (ARDS). This is a very serious condition that causes alveolar damage to the lungs, can cause pulmonary thrombosis and often requires ventilator support. A majority of patients undergoing treatment for COVID-19 in intensive care units have developed ARDS.

In a recent paper, Miklós Lipcsey and colleagues have studied components of the intravascular innate immune system (IIIS) in relation to COVID-19 ARDS.

The IIIS includes the complement, contact, coagulation, and fibrinolysis systems, and is crucial for recognizing and eliminating microorganisms and debris in the body. It is also likely to be involved in the pathogenesis of COVID-19 ARDS.

The authors studied IIIS biomarkers, including C4d using the kit from Svar Life Science, from COVID-19 patients admitted to the intensive care unit. These analyses were compared to biochemical parameters and the clinical outcome of the patients.

The researchers found a strong association between the activation of IIIS with organ damage and death. Furthermore, they found that the complement system and especially the kallikrein/kinin system are strong prognostic markers of the outcome of the patients.

These findings suggest that it may be worth using existing kallikrein/kinin inhibitors for the treatment of critically ill COVID-19 patients.
 

Read the paper (Open access)

Complement system solutions